罗浮山宫炎平品牌怎么样 申请店铺

我要投票 罗浮山宫炎平在女性洗液行业中的票数:632 更新时间:2026-01-14
罗浮山宫炎平是哪个国家的品牌?「罗浮山宫炎平」是 广东罗浮山国药股份有限公司 旗下著名品牌。该品牌发源于广东省惠州市,由创始人王 * 良在1970年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力罗浮山宫炎平品牌出海!将品牌入驻外推网,定制罗浮山宫炎平品牌推广信息,可以显著提高罗浮山宫炎平产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

罗浮山宫炎平怎么样

广东罗浮山国药股份有限公司,座落在广东罗浮山脚下,其前身——罗浮山药业始建于1970年,至今已有四十年发展史。公司投资上亿元按GMP标准建成了产、销一体的“罗浮山药业城”,占地面积10万多平方米、建筑面积8万平方米,至今已成为拥有员工近4000人、年纳税额超四千万元的大中型企业,是目前惠州市规模较大的制药企业,也是广东省内产能较大、剂型较齐全的中成药制剂企业之一。公司位于穗深经济走廊中心,旺盛的珠三角地域,毗邻港澳,交通四通八达,环境优雅。

罗浮山国药追求“以质量为本,科技创新”的经营理念,以继承和发扬具有1600多年历史的罗浮山中医药文化为已任,以造福百姓健康为宗旨,从事中西药品的开发、生产、销售以及中药材种植、生产加工和经营。四十年来,罗浮山国药不断挖掘和继承古代医药精华,利用当地丰富的中草药资源,系列颇具特色的品种、中药保护品种畅销国内外。公司现拥有的十一个剂型12条生产线全部通过国家GMP认证。年生产能力达片剂130亿片、颗粒剂3000吨、硬胶囊3亿粒、小容量注射剂2亿支、茶剂800万袋、搽剂8000万瓶、滴丸3亿粒、软胶囊2亿粒、栓剂5000万粒;提取车间年加工中药材可达2万吨,是广东省规模较大的中药提取车间之一。企业销售额每年以20-30%的幅度稳步增长。

朝气蓬勃的罗浮山国药已逐步发展壮大成为一个集科研、生产、销售和药材种植于一体的现代化高科技制药企业。随着企业不断发展壮大,坚信罗浮山国药将走在国内同行业的前列,屹立于中华药业之林。


Guangdong Luofushan Guoyao Co., Ltd. is located at the foot of Guangdong Luofushan. Its predecessor, Luofushan pharmaceutical industry, was founded in 1970 and has a history of 40 years. The company has invested more than 100 million yuan to build a "Luofushan pharmaceutical city" integrating production and marketing according to GMP standards, covering an area of more than 100000 square meters and a building area of 80000 square meters. So far, it has become a large and medium-sized enterprise with nearly 4000 employees and an annual tax payment of more than 40 million yuan. It is a large-scale pharmaceutical enterprise in Huizhou at present, and a Chinese patent medicine preparation with large production capacity and complete dosage forms in Guangdong Province One of the enterprises. The company is located in the center of suishen economic corridor, the exuberant Pearl River Delta region, adjacent to Hong Kong and Macao, with convenient transportation and elegant environment. Luofushan national medicine pursues the business philosophy of "quality-oriented, scientific and technological innovation", inherits and develops the culture of Luofushan Chinese medicine with a history of more than 1600 years, and aims to benefit the people's health. It is engaged in the development, production and sales of Chinese and Western medicine as well as the cultivation, production, processing and management of Chinese medicine. Over the past forty years, Luo Fu Shan has continuously excavated and inherited the essence of ancient medicine, and made use of the rich resources of Chinese herbal medicine, and a series of distinctive varieties and traditional Chinese medicine protection varieties have been sold well both at home and abroad. The company now has 11 dosage forms and 12 production lines, all of which have passed the national GMP certification. With an annual production capacity of 13 billion tablets, 3000 tons of granules, 300 million hard capsules, 200 million small volume injections, 8 million tea bags, 80 million bottles of liniments, 300 million drop pills, 200 million soft capsules and 50 million suppositories, the extraction workshop can process 20000 tons of traditional Chinese medicine annually, which is one of the large-scale TCM extraction workshops in Guangdong Province. The sales volume of the enterprise increases steadily by 20-30% every year. The vigorous Luofushan national medicine has gradually developed into a modern high-tech pharmaceutical enterprise integrating scientific research, production, sales and medicine planting. With the continuous development and growth of the enterprise, we firmly believe that Luofushan Guoyao will be in the forefront of the same industry in China and stand in the forest of Chinese pharmaceutical industry.

本文链接: https://brand.waitui.com/08d919ee4.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

*ST返利:终止购买广州风腾网络科技公司60%股权

36氪获悉,*ST返利公告,此前,公司全资子公司上海众彦信息科技有限公司拟以不超过2880万元的对价,购买宋瑞银、宋瑞金持有的广州风腾网络科技有限公司60%股权。因受客观因素影响,股权交割事宜尚未取得实质性进展,为提升公司资金利用效率,公司决定终止收购广州风腾网络科技有限公司60%股权的事项。

1小时前

一品红:预计2025年净亏损3.13亿元—4.42亿元

36氪获悉,一品红发布业绩预告。报告显示,预计2025年净利润亏损3.13亿元—4.42亿元,上年同期亏损5.4亿元。报告期,公司产品销售及毛利率水平有一定程度下降,加上公司广东瑞石创新原料药生产基地投入使用导致折旧摊销增加及研发持续投入,影响了公司经营业绩。

2小时前

中国联通:董事唐国良辞任

36氪获悉,中国联通公告,唐国良因工作安排原因,向中国联合网络通信股份有限公司董事会提交书面辞呈,辞去本公司董事及董事会发展战略委员会、审计与风险委员会委员职务。该辞任自2026年1月14日起生效。

2小时前

美国银行:2025全年净利润305亿美元,同比增19%

美银第四财季扣除利息支出后的营收为283.7亿美元预估为277.8亿美元;净利息收入157.5亿美元,市场预期154.8亿美元。美银第四财季不含DVA的交易收入为45.3亿美元,市场预期43.3亿美元。平均股本回报率10.5%。美银第四财季净利润76亿美元,上年同期68亿美元;2025全年净利润305亿美元,同比增19%。(财联社)

2小时前

9天6板利欧股份:目前经营情况正常,不存在公司应披露而未披露的重大事项

36氪获悉,利欧股份公告,公司股票价格于2026年1月13日、2026年1月14日连续二个交易日收盘价格涨幅偏离值累计超过20%,属于股票交易异常波动的情况。经核实,公司前期披露的信息不存在需要更正、补充之处,近期经营情况正常,内外部经营环境未发生重大变化,公司及控股股东、实际控制人不存在关于公司的应披露而未披露的重大事项,或处于筹划阶段的重大事项。

2小时前

本页详细列出关于罗浮山宫炎平的品牌信息,含品牌所属公司介绍,罗浮山宫炎平所处行业的品牌地位及优势。
咨询